News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics to Announce Third Quarter 2017 Financial Results and Recent Corporate Developments on October 25, 2017
CAMBRIDGE, Mass. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will report third quarter 2017 financial results
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Sept. 29, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on September 25, 2017 ,
View HTML
Toggle Summary Sarepta Therapeutics to Present at the 22nd International Annual Congress of the World Muscle Society
CAMBRIDGE, Mass. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will present a total of six posters at the 22 nd
View HTML
Toggle Summary Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer
The appointment of Dr. Basi, formerly the chief science and technology officer of Elan, continues to strengthen Sarepta’s leadership team as it accelerates the advancement of its rare disease pipeline CAMBRIDGE, Mass. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day
CAMBRIDGE, Mass. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will ring Nasdaq’s Closing Bell today in
View HTML
Toggle Summary Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053)
-- Study achieved statistical significance on all primary and secondary biological endpoints -- -- Results further validate the Company’s exon-skipping platform for the treatment of DMD -- CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on August 31, 2017 , that
View HTML
Toggle Summary Sarepta Therapeutics to Present at Three Upcoming Investor Conferences
CAMBRIDGE, Mass. , Aug. 24, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , July 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on July 31, 2017 , that
View HTML
Toggle Summary Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications
Data show for the first time a systemic therapeutic effect in DMD dogs using a rAAV2/8 micro-dystrophin gene therapy approach without immunosuppressive treatment CAMBRIDGE, Mass. , July 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.